Engineered OX40L CAR-Tregs
Transplant Rejection, Autoimmune Disorders
Pre-clinicalActive
Key Facts
About Regatta Bio
Regatta Bio is a private, pre-clinical-stage biotech founded in 2021 and based in Boston, MA. The company is pioneering a platform for engineered Treg cell therapies designed to restore immune tolerance in transplantation and autoimmunity. Its pipeline features a de-risked strategy, starting with ex vivo expanded Tregs and advancing to genetically modified CAR-Tregs with enhanced features like IL-2 independence and resistance to standard immunosuppressants. Backed by incubators Eos BioInnovation and Panacea Venture, Regatta is positioned to address significant unmet needs in immune-mediated diseases.
View full company profile